Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02368990
Other study ID # D5160R00001
Secondary ID
Status Withdrawn
Phase N/A
First received January 29, 2015
Last updated July 6, 2015
Start date June 2015
Est. completion date June 2018

Study information

Verified date July 2015
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Canada: Institutional Review BoardChina: Ethics CommitteeFrance: French Data Protection AuthorityFrance: The Commission nationale de l’informatique et des libertésGermany: Ministry of HealthGermany: Ethics CommissionItaly: The Italian Medicines AgencyItaly: Ethics CommitteeJapan: Institutional Review BoardMexico: Ministry of HealthMexico: Ethics CommitteeNetherlands: Medical Ethics Review Committee (METC)Russia: Ethics CommitteeSpain: Ethics CommitteeSpain: Agencia Española de Medicamentos y Productos SanitariosSweden: Institutional Review BoardTaiwan: Institutional Review BoardUnited Kingdom: Research Ethics CommitteeUnited Kingdom: National Institute for Health ResearchUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The aim of the study is to collect real world information on patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who progressed after first line treatment with an approved Tyrosine-Kinase Inhibitor (TKI), who are known to be T790M positive and have been prescribed second line platinum-based chemotherapy (Pemetrexed + Cisplatin /Carboplatin).


Description:

The study is an observational prospective cohort study that plans to enroll approximately 200 patients worldwide. There are Epidermal Growth Factor Receptor (EGFR) mutations known to be associated with EGFR-targeted TKI sensitivity ( Ex19Del, L858R, L861Q, and G719X). Further tests on biopsied tissue or cytology at progression after treatment with an approved EGFR targeted TKI are used to determine positivity to T790M mutation. Primary objectives of the study are :

- To estimate overall survival

- To estimate disease progression (as assessed and defined by physician)

- To estimate time on treatment by line of therapy

- To describe time to subsequent therapies (or death)

- To describe healthcare resource utilization patterns

- To capture patient reported symptoms, functioning, and health-related quality of life (HRQoL) data using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items (EORTC QLQ-LC13)

- To describe the use of pemetrexed + cisplatin/carboplatin as the 2nd line treatment

- To describe treatment patterns for 3rd line treatment and beyond


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Provision of signed and dated written informed consent prior to any study specific procedure.

- Patients with histologically- or cytologically-documented NSCLC who present with Stage IIIB/ Stage IV disease.

- Evidence of radiological disease progression following 1st line treatment for advanced/metastatic NSCLC with an approved EGFR-targeted TKI monotherapy without any additional concurrent NSCLC treatment. Chemotherapy received in the adjuvant setting is permitted.

- Patients prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) for 2nd line treatment of NSCLC. Treatment must have been selected by physician as part of routine standard of care, prior to confirming eligibility for the study. Patient must be enrolled into the study within two cycles of beginning treatment. Treatment must be given in accordance with local prescribing information.

- Confirmation prior to enrolment into the study that the tumour harbours the following EGFR mutations known to be associated with EGFR-targeted TKI sensitivity: Ex19Del, L858R, L861Q, and G719X.

- Patients must have had confirmation that tumour is T790M mutation positive from a biopsy or cytology sample taken after confirmed disease progression on 1st line treatment with an approved EGFR-targeted TKI.

- WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.

Exclusion Criteria:

- Treatment with any of the following:

- Prior treatment with more than one line of treatment for advanced NSCLC.

- Major surgery (excluding placement of vascular access) within 4 weeks prior to enrolment.

- Palliative radiotherapy with a limited field of radiation within 1 week prior to enrolment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks prior to enrolment.

- Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to enrolment.

- Patients who are known to be entering an alternative interventional clinical study at the time of enrolment into this study will be excluded. However, inclusion in this study does not preclude participation in any other clinical study after enrolment. Patients who participate in clinical studies after enrolment into this study will be followed to the extent possible as permitted by the sponsor of that clinical study.

- Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the site).

- Judgment by the physician that the patient should not participate in the study if the patient is unlikely to comply with procedures, restrictions, and requirements.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Locations

Country Name City State
China Research Site Beijing
China Research Site Changsha
China Research Site Guangzhou
China Research Site Jiangsu
China Research Site Jilin
China Research Site Shanghai
China Research Site Shanghai Ruijin Hospital
China Research Site Sichuan Cancer Hospital
China Research Site Xian
France Research Site Boulogne Billancourt
France Research Site Bretagne
France Research Site La Chaussee-Saint-Victor
France Research Site Lille
France Research Site Pontoise
France Research Site Rhone-Alpes
France Research Site Saint Quentin
Germany Research Site Esslingen
Italy Research Site Catania
Italy Research Site Ferrara
Italy Research Site Messina
Italy Research Site Modena
Italy Research Site Napoli
Italy Research Site Padova
Italy Research Site Parma
Italy Research Site Perugia
Italy Research Site Rome
Italy Research Site Torino
Netherlands Research Site Groningen
Russian Federation Research Site Barnaul
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site Saint- Petersburg
Spain Research Site Alicante
Spain Research Site Badalona
Spain Research Site Barcelona
Spain Research Site La Coruna
Spain Research Site Leon
Spain Research Site Lugo
Spain Research Site Madrid
Spain Research Site Ourense
Spain Research Site Pamplona
Spain Research Site Santander
Spain Research Site Sevilla
Spain Research Site Valencia
Spain Research Site Vizcaya
Taiwan Research Site LinKou
Taiwan Research Site Taichung
Taiwan Research Site Taipei
United States Research Site Kentucky Kentucky
United States Research Site Langhorne Pennsylvania
United States Research Site Maryland Maryland

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Parexel

Countries where clinical trial is conducted

United States,  China,  France,  Germany,  Italy,  Netherlands,  Russian Federation,  Spain,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival This will be assessed as the time from the start date of 2nd line chemotherapy until death due to any cause or censoring (at end of 24 months).To assess efficacy of permetrexed + cisplatinum/carboplatin as the 2nd line of treatment of NSCLC. 24 months from last subject in No
Secondary Response to Therapy as assessed by the physician This will be assessed as the time from start of 2nd line therapy until the date of disease progression or death (by any cause in the absence of progression). To assess efficacy of 2nd line treatment and beyond. 24 months from last subject in No
Secondary Time on treatment by line of therapy and between therapies This will be assessed as the time from start date of line of therapy to end date of line of therapy or death date. To describe treatment patterns for 2nd line and beyond. 24 months from last subject in No
Secondary Admission of planned/unplanned hospitalizations, emergency department visits and outpatient/physician visits This will be assessed as the number and Time from the dates of admission and exit of attendance. To describe Healthcare resource utilization for 2nd line treatment and beyond. 24 months from last subject in No
Secondary Time to symptom deterioration For each of the symptoms in EORTC QLQ-LC13 and EORTC QLQ-C30, Time from inclusion until the date of first clinically meaningful symptom deterioration or death by any cause in the absence of a clinically meaningful symptom deterioration. To assess the impact of 2nd and subsequent lines of therapy on patients' disease-related symptoms and health related quality of life. 24 months from last subject in No
Secondary Symptom Improvement Rate This will be assessed as the number of patients with two consecutive assessments, which showed a clinically meaningful improvement in that symptom from baseline. To assess the impact of 2nd and subsequent lines of therapies on patients' disease-related symptoms and health related quality of life. 24 months from last subject in No
Secondary Duration of Response as defined by the physician This will be assessed as the time from the date of complete or partial response until the first date of recurrence or progression. To assess the efficacy of 2nd line treatment and beyond. 24 months from last subject in No
Secondary Progression Free Survival This will be assessed as the time from start of 2nd line therapy until the date of disease progression or death by any cause. This will be done to assess efficacy of pemetrexed + cisplatin/carboplatin as the 2nd line treatment of NSCLC. 24 months from last subject in No
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1